The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.

Abstract:

:The small GTPase Rac1 regulates many cellular processes, including cytoskeletal reorganization, cell migration, proliferation, and survival. Additionally, Rac1 plays a major role in activating NF-κB-mediated transcription. Both Rac1 and NF-κB regulate many properties of the malignant phenotype, including anchorage-independent proliferation and survival, metastasis, and angiogenesis. Despite these findings, the roles of Rac1and NF-κB in non-small cell lung carcinoma, a leading cause of cancer deaths, have not been thoroughly investigated. Here, we compared the effects of Rac1 siRNA to that of the Rac1 inhibitor NSC23766 on multiple features of the NSCLC malignant phenotype, including NF-κB activity. We show that the siRNA-mediated silencing of Rac1 in lung cancer cells results in decreased cell proliferation and migration. The decrease in proliferation was observed in both anchorage-dependent and anchorage-independent assays. Furthermore, cells with decreased Rac1 expression have a slowed progression through the G 1 phase of the cell cycle. These effects induced by Rac1 siRNA correlated with a decrease in NF-κB transcriptional activity. Additionally, inhibition of NF-κB signaling with BAY 11-7082 inhibited proliferation; indicating that the loss of cell proliferation and migration induced by the silencing of Rac1 expression may be attributed in part to loss of NF-κB activity. Interestingly, treatment with the Rac1 inhibitor NSC23766 strongly inhibits cell proliferation, cell cycle progression, and NF-κB activity in lung cancer cells, to an even greater extent than the inhibition induced by Rac1 siRNA. These findings indicate that Rac1 plays an important role in lung cancer cell proliferation and migration, most likely through its ability to promote NF-κB activity, and highlight Rac1 pathways as therapeutic targets for the treatment of lung cancer.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Gastonguay A,Berg T,Hauser AD,Schuld N,Lorimer E,Williams CL

doi

10.4161/cbt.20082

subject

Has Abstract

pub_date

2012-06-01 00:00:00

pages

647-56

issue

8

eissn

1538-4047

issn

1555-8576

pii

20082

journal_volume

13

pub_type

杂志文章
  • Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

    abstract::KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28550

    authors: Tong JH,Lung RW,Sin FM,Law PP,Kang W,Chan AW,Ma BB,Mak TW,Ng SS,To KF

    更新日期:2014-06-01 00:00:00

  • Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.

    abstract::In bone metastases, tumor cells interact with the bone microenvironment to induce osteoclastogenesis, leading to bone destruction and the growth factor release.  RANK ligand (RANKL) is essential for osteoclast formation, function, and survival.  Tumor cell-mediated osteolysis is thought to occur ultimately via inducti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.7.11266

    authors: Holland PM,Miller R,Jones J,Douangpanya H,Piasecki J,Roudier M,Dougall WC

    更新日期:2010-04-01 00:00:00

  • The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.

    abstract::Farnesyltransferase inhibitors (FTIs) have been demonstrated to induce growth arrest or apoptosis independent of Ras mutation. Alternatively, Akt has been proposed as a potential target for the FTI's actions. This study investigated whether Lonafarnib was effective in inhibiting the growth of human nonsmall cell lung ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.11.1176

    authors: Sun SY,Zhou Z,Wang R,Fu H,Khuri FR

    更新日期:2004-11-01 00:00:00

  • Telomerase as a target for cancer immunotherapy.

    abstract::Telomerase is the ribonucleoprotein that enables cancer and stem cells to maintain their telomeres, resulting in unlimited proliferative potential. The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.2.255

    authors: Nguyen B,Elmore LW,Holt SE

    更新日期:2003-03-01 00:00:00

  • Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.

    abstract::Epithelial-mesenchymal transition (EMT) is a critical early event in tumorigenesis. The contribution of heparan sulfate (HS) to EMT has not been fully elucidated. HS D-glucosaminyl 3-O-sulfotransferase-3B1 (3-OST-3B1) participates in the final step of HS fine structure biosynthesis, whose involvement in cancer has yet...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.5.15957

    authors: Song K,Li Q,Jiang ZZ,Guo CW,Li P

    更新日期:2011-09-01 00:00:00

  • Preliminary investigation of the inhibitory effects of the tyroservaltide (YSV) tripeptide on human hepatocarcinoma BEL-7402.

    abstract::This study aimed to investigate the inhibitory effect of tyroservaltide (YSV) on the human hepatocarcinoma BEL-7402 transplanted into nude mice and to explore its possible anti-tumor mechanism. Nude mice bearing xenografts of the human BEL-7402 hepatoma were given daily i.p. injections of YSV or saline (as a control) ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.9.1968

    authors: Jia J,Lu R,Qiu S,Li H,Che X,Zhao P,Jin M,Yang H,Lin G,Yao Z

    更新日期:2005-09-01 00:00:00

  • CIP2A expression and localization in oral carcinoma and dysplasia.

    abstract:AIMS:Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity resulting in severe morbidity and mortality. To date only few proteins have been suggested as potential biomarkers or targets for this type of cancer. Cancerous inhibitor of PP2A (CIP2A) is a protein expressed in epithelial tis...

    journal_title:Cancer biology & therapy

    pub_type: 评论,杂志文章

    doi:10.4161/cbt.10.7.12895

    authors: Katz J,Jakymiw A,Ducksworth MK,Stewart CM,Bhattacharyya I,Cha S,Chan EK

    更新日期:2010-10-01 00:00:00

  • Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

    abstract::Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying tumor types including metastatic colorectal cancer. Many patients treated with anti-EGFR therapy however do not respond and those that do initially respond often acquire resistance. Here we...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28179

    authors: Ung N,Putoczki TL,Stylli SS,Ng I,Mariadason JM,Chan TA,Zhu HJ,Luwor RB

    更新日期:2014-05-01 00:00:00

  • 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.

    abstract::Resistance of tumors due to restricted drug accumulation and reversal of DNA lesions in tumor cells as well as normal tissue toxicity limit the efficacy of topoisomerase inhibition based anticancer drugs. It has been proposed that selective inhibition of energy dependent repair processes and enhanced retention of drug...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.9.1040

    authors: Dwarakanath BS,Khaitan D,Ravindranath T

    更新日期:2004-09-01 00:00:00

  • Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

    abstract::There is an urgent need to develop new strategies to treat ovarian cancer, the most deadly gynecologic malignancy. Histone deacetylase (HDAC) inhibitors are emerging as novel therapeutic drugs in the treatment of a variety of cancers, including those resistant to standard chemotherapy. Since there are multiple HDAC is...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.5.4007

    authors: Khabele D,Son DS,Parl AK,Goldberg GL,Augenlicht LH,Mariadason JM,Rice VM

    更新日期:2007-05-01 00:00:00

  • Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

    abstract::Patients with serosal (pleural or peritoneal) spread of malignancy have few definitive treatment options and consequently have a very poor prognosis. We have previously shown that photodynamic therapy (PDT) can be an effective treatment for these patients, but that the therapeutic index is relatively narrow. Here, we ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.22256

    authors: Edmonds C,Hagan S,Gallagher-Colombo SM,Busch TM,Cengel KA

    更新日期:2012-12-01 00:00:00

  • Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases.

    abstract::Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1831370

    authors: Xuan L,Sun B,Meng X,Liu C,Cong Y,Wu S

    更新日期:2020-11-01 00:00:00

  • Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.

    abstract::Cytotoxic chemotherapeutic drugs, especially when used in combination, are widely employed to treat a variety of cancers in patients but often lead to serious symptoms that negatively affect physical functioning and quality of life. There is compelling evidence that implicates cytotoxic chemotherapy-induced inflammati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29922

    authors: Wong J,Tran LT,Magun EA,Magun BE,Wood LJ

    更新日期:2014-10-01 00:00:00

  • The promising role of nivolumab in renal cell cancers.

    abstract::The therapeutic efficacy of checkpoint inhibitors across numerous tumor types has resulted in approval for neoplasms such as melanoma and lung cancer. Nivolumab is a fully humanized IgG4 antibody that inhibits immune checkpoint between programmed death 1 (PD-1) on T cells and PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139269

    authors: Gupta K,Tiu DY,Tiu J,Aragon-Ching JB

    更新日期:2016-01-01 00:00:00

  • Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is caused by the abnormal accumulation of non-functional B-cells in peripheral blood and bone marrow. However, the precise aetiology and mechanism of the disease are unclear. Recently, progress has been made in the identification of both the genetic deficiencies and environmen...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.7.2.5262

    authors: Chen J,McMillan NA

    更新日期:2008-02-01 00:00:00

  • Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.

    abstract::Antiangiogenic or metronomic chemotherapy, the frequent administration of conventional cytotoxic agents at low doses, is believed to target activated tumor endothelial cells. The mechanisms of action of such regimen remain poorly understood. In the March 2004 issue of Cancer Research, Hamano et al. demonstrated that l...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.3.12.1369

    authors: Ng SS,Figg WD

    更新日期:2004-12-01 00:00:00

  • Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.

    abstract::bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission. In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphat...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.10.17674

    authors: Tao K,Li YJ,Wang D,Qi JY,Deng YP,Wang HX,Hu J,Feng WL

    更新日期:2011-11-15 00:00:00

  • Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines.

    abstract::TPCK is widely used as an inhibitor of chymotrypsin-like proteases but has recently been identified as an inhibitor of the PDK1/Akt pathway. In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. The inhibitory a...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.8.970

    authors: Rokhlin OW,Guseva NV,Taghiyev AF,Glover RA,Cohen MB

    更新日期:2004-08-01 00:00:00

  • EphA2 as a promoter of melanoma tumorigenicity.

    abstract::The greatest health threat from malignant melanoma is death due to metastatic disease. Consequently, the identification of markers predictive of metastatic disease is essential for identifying new therapeutic targets. EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to b...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.3.7485

    authors: Margaryan NV,Strizzi L,Abbott DE,Seftor EA,Rao MS,Hendrix MJ,Hess AR

    更新日期:2009-02-01 00:00:00

  • The genetics of FANCC and FANCG in familial pancreatic cancer.

    abstract::Patients with Fanconi anemia (FA) display a wide variety of defects including bone marrow failure and a high risk of developing cancer. Multiple Fanconi genes exist whose proteins form a complex that along with BRCA1 is important for the translocalization of FANCD2 to nuclear foci. With BRCA2 and RAD51, this complex i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.2.609

    authors: Rogers CD,van der Heijden MS,Brune K,Yeo CJ,Hruban RH,Kern SE,Goggins M

    更新日期:2004-02-01 00:00:00

  • Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy.

    abstract::The role of immunotherapy in combination with traditional treatment regime in improving the survival of cancer patients has attracted more and more attention. Especially the abscopal effect that describes the phenomenon of localized radiotherapy leading to regression of distant unirradiated tumors and the role of enha...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1276133

    authors: Shi F,Wang X,Teng F,Kong L,Yu J

    更新日期:2017-03-04 00:00:00

  • Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

    abstract::While several hypotheses have been put forward to explain how prostate tumors become resistant to androgen deprivation therapy, the mechanism by which prostate tumors have increased androgen concentrations as compared to the serum has been poorly explored. Using a stromal/epithelial cell co-culture model, Mizokami et ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.3.11143

    authors: Sharma H,Sissung TM,Pressler H,Figg WD

    更新日期:2010-02-01 00:00:00

  • Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis.

    abstract::Background: Associations between polymorphisms in interleukin-10 (IL-10) and hematological oncology were already explored by many genetic association studies, with controversial findings. The aim of this meta-analysis was to more comprehensively analyze associations between polymorphisms in IL-10 and hematological onc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1702404

    authors: Hong P,Feng WY,Fu LH,Jin J,Fu JP

    更新日期:2020-04-02 00:00:00

  • Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

    abstract::Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.7.15980

    authors: Paradziej-Łukowicz J,Skwarska A,Peszyńska-Sularz G,Brillowska-Dąbrowska A,Konopa J

    更新日期:2011-10-01 00:00:00

  • Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

    abstract::Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refractory pancreatic canc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.986967

    authors: Samulitis BK,Pond KW,Pond E,Cress AE,Patel H,Wisner L,Patel C,Dorr RT,Landowski TH

    更新日期:2015-01-01 00:00:00

  • Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.

    abstract::Alterations in the function of cell cycle checkpoints are frequently detected in oral squamous cell carcinomas (OSCCs), and are often associated with the sensitivity of the cancer cells to chemotherapeutic drugs. Recently, a mitotic checkpoint gene, Chfr, was shown to be inactivated by promoter methylation and point m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.7.1896

    authors: Ogi K,Toyota M,Mita H,Satoh A,Kashima L,Sasaki Y,Suzuki H,Akino K,Nishikawa N,Noguchi M,Shinomura Y,Imai K,Hiratsuka H,Tokino T

    更新日期:2005-07-01 00:00:00

  • Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.

    abstract::The 26S proteasome is a large multi-subunit protein complex found in the cytoplasm and nucleus of mammalian cells which plays a critical role in intracellular proteolysis. It has been found that the 26S proteasome degrades multiple important substrates which are associated with tumor growth and development. Emerging e...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.7.2971

    authors: Fribley A,Wang CY

    更新日期:2006-07-01 00:00:00

  • The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.

    abstract:BACKGROUND:IL-24 (interleukin-24) is a promising, multi-functional anti-cancer agent able to selectively induce tumor cell apoptosis while sparing normal cells. Additionally, IL-24 can enhance the immune response to tumors and suppress tumor angiogenesis. In this study, we introduced IL-24 into the oncolytic adenovirus...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.3.12308

    authors: Xiao LL,Wu YM,Qian J,Tan Y,Xie GL,Zhang KJ,Wang YG,Jia XY,Liu XY

    更新日期:2010-08-01 00:00:00

  • Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes.

    abstract::Retinoids are used in leukemia therapy and chemoprevention of cancers. Treatment of MCF-7 breast carcinoma cells with low doses of retinoids induces gradual proliferation arrest with phenotypic markers of senescence. cDNA microarray hybridization and reverse transcription-polymerase chain reaction analysis showed that...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.1.1.35

    authors: Dokmanovic M,Chang BD,Fang J,Roninson IB

    更新日期:2002-01-01 00:00:00

  • Heparan sulfate proteoglycans as targets for cancer therapy: a review.

    abstract::Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1838034

    authors: Onyeisi JOS,Ferreira BZF,Nader HB,Lopes CC

    更新日期:2020-12-01 00:00:00